teaser
A recent report has suggested the pharmaceutical market in Switzerland is among the most advanced in the world, with per-capita expenditure one of the highest, at an estimated $743.4 in 2006.
The study, by Ireland-based research firm Research and Markets, found that drug consumption centred on patented pharmaceuticals, due to Switzerland’s ready market for the latest branded drugs.
The report also found that high levels of out-of-pocket expenditure have led to the development of a competitive consumer health market, forecast to expand at a compound annual growth rate of 5.73% to reach a the level of $7.69 billion by the end of the forecast period.
The Swiss industry has seen lots of recent market activity, with Novartis announcing a large-scale restructuring scheme with the loss of 2,500 jobs, Galenica acquiring Canadian biotech firm Aspreva in a $900 million deal, and Sandoz launching the primary ingredient in Amgen’s blockbuster anaemia treatment Epogen.
